Stoke Therapeutics (STOK) Accounts Payables (2018 - 2026)

Stoke Therapeutics has reported Accounts Payables for 9 years, with the latest figure at $6.8 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 212.85% year-over-year to $6.8 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (up 212.85% YoY), and the FY2025 full-year result was $4.9 million, up 97.72% from the prior year.
• Accounts Payables for Q1 2026 stood at $6.8 million, up from $4.9 million in the prior quarter.
• The five-year high for Accounts Payables was $6.8 million in Q1 2026, with the low at $766000.0 in Q4 2022.
• Average Accounts Payables over 5 years is $3.3 million, with a median of $3.1 million recorded in 2023.
• Peak annual rise in Accounts Payables reached 274.04% in 2022, while the deepest fall reached 67.88% in 2022.
• Tracing STOK's Accounts Payables over 5 years: stood at $766000.0 in 2022, then jumped by 121.28% to $1.7 million in 2023, then jumped by 47.37% to $2.5 million in 2024, then surged by 97.72% to $4.9 million in 2025, then jumped by 38.47% to $6.8 million in 2026.
• The last three Accounts Payables figures came in at $6.8 million (Q1 2026), $4.9 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.

Peer Comparison